PPD, Inc. (PPD), together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide.
The company operates through two segments, Clinical Development Services and Laboratory Services.
It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services.
The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants.
As the stock has gained 123% increase in shareholders over the last year and given that share prices are up 11% since last quarter, this stock should continue to head higher on its upward share price rally.
Entry Point: $37.00
Trading Range: $16.22 - $38.76
Stop Loss: $35.15
Target Price: $47.10
PPD closed at $46.00